Company / Cash & Equivalents
Veracyte, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$362.6M
FY2025
5-year range
$154.2M / $362.6M
FY2021-FY2025
Trend
+51.7%
vs FY2024
Sector context
#59 of 148
Health Care
What the data says
At $363M, Veracyte, Inc.'s cash & equivalents ranks #59 of 148 in the Health Care sector. Cash & Equivalents has increased for 3 consecutive years, from $154M in FY2022 to $363M in FY2025.
Based on SEC 10-K filings.
$363M in FY2025 with a 5-year CAGR of +17.9%.
Improved from $216M to $363M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +33.0%
- 5-Year CAGR
- +17.9%
- 10-Year CAGR
- -
Sector benchmark
#59 of 148 in Health CareTop 40% of 148This company $362.6M Sector average $1.2B
▼
-69.2% below sector average
Key checks
Key Insights
- Veracyte, Inc.'s cash & equivalents has grown for 3 consecutive years.
- 5-year CAGR of +17.9%, indicating consistent growth.
- In FY2025, cash & equivalents increased 51.7% year-over-year.
- Ranks #59 out of 148 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 6.19 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $362.6M | +51.7% |
| FY2024 | $239.1M | +10.5% |
| FY2023 | $216.5M | +40.3% |
| FY2022 | $154.2M | -10.9% |
| FY2021 | $173.2M | +8.7% |
| FY2020 | $159.3M | +0.0% |
| FY2019 | $159.3M | +104.3% |
| FY2018 | $78.0M | +31.7% |
| FY2017 | $59.2M | +69.1% |
| FY2016 | $35.0M | -10.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026